CHMP’s January Recommendations Include Tofacitinib And Biosimilar Adalimumab
Executive Summary
The European Medicines Agency’s Committee for Medicinal Products for Human Use notes also that Sandoz withdrew its application for the biosimilar Zioxtenzo (pegfilgrastim).